| Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... New England journal of medicine 369 (2), 134-144, 2013 | 4240 | 2013 |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016 | 3903 | 2016 |
| Early childhood development coming of age: science through the life course MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ... The lancet 389 (10064), 77-90, 2017 | 3099 | 2017 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2259 | 2017 |
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ... The Lancet 384 (9948), 1109-1117, 2014 | 2154 | 2014 |
| Association of pembrolizumab with tumor response and survival among patients with advanced melanoma A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ... Jama 315 (15), 1600-1609, 2016 | 1173 | 2016 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1146 | 2018 |
| Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... Annals of Oncology 30 (4), 582-588, 2019 | 908 | 2019 |
| NRAS mutation status is an independent prognostic factor in metastatic melanoma JA Jakob, RL Bassett Jr, CS Ng, JL Curry, RW Joseph, GC Alvarado, ... Cancer 118 (16), 4014-4023, 2012 | 866 | 2012 |
| Evaluation of immune-related response criteria and RECIST v1. 1 in patients with advanced melanoma treated with pembrolizumab FS Hodi, WJ Hwu, R Kefford, JS Weber, A Daud, O Hamid, A Patnaik, ... Journal of Clinical Oncology 34 (13), 1510-1517, 2016 | 780 | 2016 |
| Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody Pembrolizumab in melanoma AI Daud, JD Wolchok, C Robert, WJ Hwu, JS Weber, A Ribas, FS Hodi, ... Journal of Clinical Oncology 34 (34), 4102-4109, 2016 | 669 | 2016 |
| Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma C Robert, A Ribas, O Hamid, A Daud, JD Wolchok, AM Joshua, WJ Hwu, ... Journal of clinical oncology 36 (17), 1668-1674, 2018 | 486 | 2018 |
| Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology DG Coit, JA Thompson, MR Albertini, C Barker, WE Carson, C Contreras, ... Journal of the National Comprehensive Cancer Network 17 (4), 367-402, 2019 | 413 | 2019 |
| Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington, S Wardell, C Liu, ... Clinical Cancer Research 18 (19), 5329-5340, 2012 | 336 | 2012 |
| High response rate to PD-1 blockade in desmoplastic melanomas Z Eroglu, JM Zaretsky, S Hu-Lieskovan, DW Kim, A Algazi, DB Johnson, ... Nature 553 (7688), 347-350, 2018 | 332 | 2018 |
| Therapy for metastatic melanoma: the past, present, and future L Finn, SN Markovic, RW Joseph BMC medicine 10, 1-10, 2012 | 297 | 2012 |
| Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy A Swaika, WA Hammond, RW Joseph Molecular immunology 67 (2), 4-17, 2015 | 290 | 2015 |
| Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab RW Joseph, J Elassaiss-Schaap, R Kefford, WJ Hwu, JD Wolchok, ... Clinical Cancer Research 24 (20), 4960-4967, 2018 | 286 | 2018 |
| NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines SM Swetter, JA Thompson, MR Albertini, CA Barker, J Baumgartner, ... Journal of the National Comprehensive Cancer Network 19 (4), 364-376, 2021 | 285 | 2021 |
| Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology DG Coit, JA Thompson, A Algazi, R Andtbacka, CK Bichakjian, ... Journal of the National Comprehensive Cancer Network 14 (4), 450-473, 2016 | 256 | 2016 |
Adil DaudProfessor of Medicine, University of California, San FranciscoEmail verificata su ucsf.edu